---
document_datetime: 2026-02-20 15:11:10
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/vfend-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: vfend-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.5892259
conversion_datetime: 2026-02-25 11:57:16.147569
docling_version:
  docling-serve: 1.13.1
  docling-jobkit: 1.11.0
  docling: 2.74.0
  docling-core: 2.65.2
  docling-ibm-models: 3.11.0
  docling-parse: 5.3.4
  python: cpython-313 (3.13.11)
  plaform: macOS-26.3-arm64-arm-64bit-Mach-O
---
## Vfend

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                         |
|----------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------|
| Variation type II /  | This was an application for a variation | 11/12/2025                          | 10/02/2026                                  | SmPC and PL                      | In Section 4.3 of the SmPC, eplerenone (used to |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000284468                     | following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of sections 4.3 and 4.5 of the SmPC in order to add a contraindication regarding concomitant use with eplerenone and with voclosporin based on postmarketing data and literature. The Package Leaflet is updated accordingly.   |            | treat heart and/or blood vessel problems) and voclosporin (used to treat immune disorders) were added to the list of medicinal products for which co- administration of voriconazole is contraindicated. In Section 4.5 of the SmPC, the 'interaction table' was updated to include eplerenone and voclosporin, with respective explanatory text under the column 'interaction geometric mean changes' and the resulting recommendations concerning coadministration. Section 2 of the PL was amended, accordingly. For more information, please refer to the Summary of Product Characteristics.   |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA / EMA/VR/0000316211 | B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted                                                                                                                                                                                                                                                                                                                                      | 04/12/2025 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Variation type IA / EMA/VR/0000254602 | A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active                                                                                                                                                                                                                                                                         | 07/03/2025 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|